- Home
- MNPR vs KELYB Comparison
MNPR vs KELYB Comparison
Compare MNPR & KELYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- KELYB
- Stock Information
- Founded
- MNPR 2014
- KELYB 1946
- Country
- MNPR United States
- KELYB United States
- Employees
- MNPR N/A
- KELYB N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- KELYB Professional Services
- Sector
- MNPR Health Care
- KELYB Consumer Discretionary
- Exchange
- MNPR Nasdaq
- KELYB Nasdaq
- Market Cap
- MNPR 390.5M
- KELYB 389.9M
- IPO Year
- MNPR 2019
- KELYB N/A
- Fundamental
- Price
- MNPR $86.16
- KELYB $11.06
- Analyst Decision
- MNPR Strong Buy
- KELYB
- Analyst Count
- MNPR 12
- KELYB 0
- Target Price
- MNPR $96.64
- KELYB N/A
- AVG Volume (30 Days)
- MNPR 97.3K
- KELYB 215.0
- Earning Date
- MNPR 11-10-2025
- KELYB 11-06-2025
- Dividend Yield
- MNPR N/A
- KELYB 2.56%
- EPS Growth
- MNPR N/A
- KELYB N/A
- EPS
- MNPR N/A
- KELYB N/A
- Revenue
- MNPR N/A
- KELYB $4,495,900,000.00
- Revenue This Year
- MNPR N/A
- KELYB $4.55
- Revenue Next Year
- MNPR N/A
- KELYB $5.01
- P/E Ratio
- MNPR N/A
- KELYB N/A
- Revenue Growth
- MNPR N/A
- KELYB 0.97
- 52 Week Low
- MNPR $12.55
- KELYB $11.04
- 52 Week High
- MNPR $105.00
- KELYB $19.82
- Technical
- Relative Strength Index (RSI)
- MNPR 57.75
- KELYB 36.66
- Support Level
- MNPR $77.00
- KELYB $12.96
- Resistance Level
- MNPR $89.32
- KELYB $13.47
- Average True Range (ATR)
- MNPR 7.00
- KELYB 0.04
- MACD
- MNPR -1.45
- KELYB -0.34
- Stochastic Oscillator
- MNPR 44.25
- KELYB 0.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About KELYB Kelly Services Inc. Class B
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.